The Trump administration announced 100% tariffs on patented pharmaceutical imports, targeting drugmakers that have not struck deals to lower U.S. drug prices. Larger companies have 120 days before the tariff takes effect, while smaller firms relying on contract manufacturers get 180 days. Companies that commit to building domestic manufacturing will face a lower 20% rate, rising to 100% after four years.

Several major trading partners negotiated separate rates: the EU, Japan, South Korea, and Switzerland will pay 15%, while the UK faces 10%. Generic drugs, biosimilars, animal health products, and treatments for rare diseases are exempt for now, though the administration plans to reassess in one year.

The move marks the most aggressive use of tariffs to reshape pharmaceutical supply chains in modern U.S. history. Industry analysts at ING note the immediate impact may be limited since many companies are already in pricing negotiations, but the long-term signal is clear: build in America or pay the price.